The diagnosis of renal anemia is routinely performed and relatively straightforward, while treatment with highly effective erythropoietin-stimulating agents is widely available in all major markets. However, the extremely high cost of treatment prevents many healthcare providers from delivering this treatment to all eligible patients.
Scope
What are the current definitions, pathophysiological stages and the classification of renal anemia?
What are the currently available diagnostic methods, the issues and the unmet needs in diagnosis and early detection of renal anemia?
What is the current state of pharmacological management, available treatment approaches in renal anemia, unmet needs and future trends?
What are the current issues and the commercial landscape of renal anemia marketplace?
Highlights
In Europe, biogeneric epoetins were expected to address the cost issue, however, so far they have not been particularly well received. This seems to be mostly due to physician conservatism and the fear of poor generic drug quality with attendant higher risk of side effects. Only Germany has displayed any degree of enthusiasm for biogenerics.
A number of large clinical trials, such as CHOIR and CREATE, have demonstrated some controversial results with regards to the relative inefficiency of higher hemoglobin targets. This has encouraged healthcare providers to be conservative in the choice of epoetin therapy creating an additional barrier to epoetin revenue growth.
New epoetin drug therapies predominantly address the length of drug action, allowing for less frequent administration, but unfortunately they provide neither substantial superiority nor significant reduction of costs. In addition, a very small upcoming pipeline does not yet promise any advancement in the area of superiority or reduction of cost.
Reasons to Purchase
Understand current definitions, diagnostic methods and treatment approaches in renal anemia
Current challenges and future opportunities in renal anemia management
Differences, advantages and disadvantages of pharmacological disease management
(0 items)
